Suchergebnisse - "Pineda, Juan A"

PubPharm (43)

1

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

enthalten in: Gastroenterology | 2018

von Esteban, R. | Pineda, J. | Calleja, J. | +19

CommentIn: Gastroenterology. 2018 Oct;155(4):969-971. - PMID 30201359

2

Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

enthalten in: HIV clinical trials | 2018

von Pineda, J. | Rivero-Juárez, A. | de Los Santos, I. | +11

3

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection : Real-Life Safety and Efficacy

enthalten in: PloS one | 2015

von Neukam, K. | Munteanu, D. | Rivero-Juárez, A. | +16

4

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection

enthalten in: PloS one | 2015

von Macías, J. | López-Cortés, L. | Téllez, F. | +7

5

Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection

enthalten in: Antiviral therapy | 2015

von Neukam, K. | Munteanu, D. | Haubitz, S. | +10

6

A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2014

von Real, L. | Caruz, A. | Rivero-Juarez, A. | +7

7

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy

enthalten in: The Journal of infection | 2014

von Rivero-Juarez, A. | Neukam, K. | Labarga, P. | +7

8

A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2014

von Rivero-Juarez, A. | López-Cortés, L. | Camacho, A. | +7

9

Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV

enthalten in: The Lancet. Infectious diseases | 2014

von Rivero-Juarez, A. | Lopez-Cortes, L. | Girón-Gonzalez, J. | +3

CommentOn: Lancet Infect Dis. 2013 Jul;13(7):597-605. - PMID 23768747

10

HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients

enthalten in: PloS one | 2014

von Rivero-Juarez, A. | López-Cortés, L. | Camacho, A. | +7

1
2
3
4
5
Nächster »
[5]